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Brivaracetam (Briviact)
A Novel Adjunctive Therapy for Partial-Onset Seizures
Farbod Khaleghi, PharmD Candidate; and Eric C. Nemec II, PharmD, BCPS

INTRODUCTION

Epilepsy is the fourth most common
neurological disorder and affects more
than 65 million individuals worldwide.1
This condition is marked by the presence
of epileptic seizures, which result from an
abnormal synchronous firing of excitatory
neurons in the brain.1,2 When neurons fire
synchronously, a wave of depolarization
known as a paroxysmal depolarizing shift
occurs.2 During this period, the neurons
experience a lowered resistance to firing,
leading to multiple action potentials that
generate abnormally increased electrical
activity within the brain.
There are various types of epilepsy
syndromes that are defined based on a
combination of symptoms. While generalized seizures begin in both hemispheres
of the brain, partial-onset seizures (POS)
(also called focal or localized seizures)
and other forms of epilepsy originate in
only one hemisphere. Patients presenting
with new-onset seizures must be carefully
evaluated to determine if the seizures are
secondary to non-neurological causes;
differential diagnoses may include hypoglycemia, alcohol withdrawal, or electrolyte abnormalities. Diagnosis of epilepsy
involves ruling out these other etiologies
via laboratory testing, brain imaging, and
an electroencephalogram. Patients with
epilepsy may have developed the condition secondary to genetic factors or
other pathologies, such as brain trauma,
malignancy, stroke, or neurological
infection.1,2 While a majority of patients
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with epilepsy are able to maintain seizure control with one to two antiepileptic
drugs (AEDs), many individuals require
adjunctive therapy to achieve long-term
remission.
Brivaracetam (Briviact, UCB, Inc.), a
propyl analogue of levetiracetam, an anticonvulsant and racetam derivative, was
granted Food and Drug Administration
(FDA) approval as an add-on therapy in
February 2016. It is indicated as adjunctive therapy for treating POS in adults
and adolescents 16 years of age or older.3

MECHANISM OF ACTION

Brivaracetam is a third-generation
antiepileptic racetam derivative and a
4-n-propyl analogue of levetiracetam.1–3
While the exact mechanism of action
of brivaracetam is unknown, its anticonvulsant effects are believed to be due
to its highly selective affinity for synaptic
vesicle protein 2A (SV2A) in the brain.
The SV2A glycoprotein is a proteincoding gene implicated in synaptic signal
transduction.4 It is believed to play a role
in the regulation of neurotransmission
by stimulating vesicle fusion and maintaining a reserve of secretory vesicles.4
Studies in SV2A-deficient animals have
demonstrated an increased propensity
for seizures.5 Brivaracetam’s actions as an
SV2A ligand lend it broad-spectrum activity against POS. Its chemical structure is
shown in Figure 1.
Figure 1 Chemical Structure
Of Brivaracetam3

PHARMACOKINETICS

Brivaracetam exhibits linear and
time-independent pharmacokinetics at
its approved doses. It is freely soluble
in water, ethanol, methanol, and glacial
acetic acid.3 The drug experiences nearcomplete absorption after oral administration and is weakly bound to plasma
proteins.3 Brivaracetam’s volume of distribution is 0.5 L/kg, and it is rapidly and
evenly distributed in most tissues. In addition, the amide moiety of the drug molecule undergoes hydrolysis via hepatic
and extrahepatic amidase to a carboxylic
acid metabolite.3 This reaction is mediated mainly by cytochrome P450 2C19
(CYP2C19). Genetic polymorphisms
in CYP2C19 may cause production of
the metabolite to be decreased. Poor
metabolizers or patients taking concurrent CYP2C19 inhibitors may require
dose reduction. Finally, brivaracetam is
excreted primarily in the urine within
72 hours of intake.3

CLINICAL TRIALS

The efficacy of brivaracetam as an
adjunctive therapy for POS was established in several randomized controlled
trials. Phase 3 trial data follow. (See
Table 1 for a summary.)

Ryvlin et al.6

A phase 3, double-blind, randomized,
placebo-controlled trial conducted across
88 centers throughout Europe and India
evaluated brivaracetam versus placebo in
399 adults with POS. The objective of the
study was to evaluate the efficacy, safety,
and tolerability of brivaracetam versus
placebo in patients with uncontrolled POS
despite adequate therapy with one or two
concomitant AEDs.
Eligible patients were randomized
to receive brivaracetam 20 mg per day
(BRV20), 50 mg per day (BRV50), 100 mg
per day (BRV100), or placebo, administered twice daily in equal doses. The
primary endpoint was percent reduction
in baseline-adjusted POS frequency per
week over the 12-week treatment period
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Table 1 A Summary of Phase 3 Trials of Brivaracetam as an Adjunctive Therapy for Partial-Onset Seizures in Adults
Study

Design

Population

Ryvlin et al.
Patients with
Prospective, multi
(2014)6
uncontrolled focal
center, double(NCT00490035) blind, randomized, seizures despite
treatment with
placebo1–2 AEDs
controlled
Biton et al.
(2014)7
(NCT00464269)

Number
(ITT)

Male
Gender
(n [%])

Placebo

100

54 (54.0)

Age in Years Duration of Median Reduction
in Baseline(mean [SD])
Epilepsy
Adjusted POS
in Years
Frequency per
(mean [SD])
Week (%)
36.4 (13.0)

20.4 (12.3)

17.0

20 mg

99

61 (61.6)

35.7 (12.5)

22.1 (13.6)

30.0 (P = 0.019)

50 mg

99

54 (54.5)

38.9 (13.6)

22.3 (13.0)

26.8 (P = 0.092)

100 mg

100

58 (58.0)

38.0 (13.1)

22.1 (12.8)

32.5 (P = 0.004)

Patients with
Prospective, multi
Placebo
center, random well-characterized
5 mg
partial epilepsy
ized, double-blind,
placebo-controlled, not fully controlled 20 mg
despite treatment
parallel-group,
50 mg
with 1–2 AEDs
fixed-dose

98

43 (43.9)

37.5 (12.6)

24.3 (12.2)

17.8

97

49 (50.5)

38.9 (11.6)

22.2 (12.1)

20.0

100

52 (52.0)

37.3 (13.3)

22.9 (14.0)

22.5

101

51 (50.5)

38.9 (12.3)

26.2 (12.0)

30.5 (P = 0.003)

Placebo

259

133 (50.9)

39.8 (12.5)

22.7 (13.3)

17.6

100 mg

252

102 (40.3)

39.1 (13.4)

22.2 (13.3)

37.2 (P < 0.001)

200 mg

249

133 (53.2)

39.8 (12.8)

23.4 (14.6)

35.6 (P < 0.001)

Placebo

121

69 (57.0)

36.5 (11.5)

–

18.9

BRV

359

181 (50.4)

35.6 (11.5)

–

26.9 (P = 0.070)

Klein et al.
Prospective, multi
(2014)8
center, double(NCT00490035) blind, randomized,
placebocontrolled
Kwan et al.
(2014)9
(NCT00504881)

Group

Patients with
uncontrolled POS
despite ongoing
treatment with
1–2 AEDs

Prospective, multi Patients with focal
or generalized
center, random
epilepsy
ized, double-blind,
placebo-controlled, uncontrolled on
1–3 AEDs
flexible dose

AEDs = antiepileptic drugs; BRV = brivaracetam; ITT = intention to treat; POS = partial-onset seizure; SD = standard deviation.

versus placebo. Secondary endpoints
included median percent reduction from
baseline in POS frequency per week, 50%
or greater responder rate, and seizure
freedom from all seizure types.
Ultimately, the study did not meet
its primary efficacy endpoint. Percent
reduction in baseline-adjusted POS frequency per week over placebo was 6.8%
for BRV20 (P = 0.239), 6.5% for BRV50
(P = 0.261), and 11.7% for BRV100
(P = 0.019). However, median percent
reduction from baseline in POS frequency
per week was 30.0% for BRV20 (P = 0.019),
26.8% for BRV50 (P = 0.092), and 32.5% for
BRV100 (P = 0.004), compared with 17%
for placebo. Adverse events are listed in
Table 2. The study concluded that while
the primary efficacy analysis based on
the BRV50 dose was not statistically significant, BRV100 significantly reduced
POS frequency per week versus placebo.

Biton et al.7

A phase 3, prospective, multicenter,
randomized, double-blind, placebocontrolled, parallel-group, fixed-dose

trial conducted across 85 centers in
Australia, Brazil, Canada, Mexico, and
the U.S. evaluated brivaracetam versus
placebo in 400 patients. The purpose of
the study was to evaluate the efficacy,
safety, and tolerability of brivaracetam
compared with placebo in patients with
uncontrolled POS.
Eligible patients were randomized
to receive BRV5, BRV20, BRV50, or
placebo, administered twice daily in equal
doses. The primary endpoint was percent reduction over placebo in baselineadjusted POS frequency per week over
the 12-week treatment period. Secondary
endpoints included median percent reduction from baseline in POS frequency per
week and 50% or greater responder rate.
Percent reduction in POS frequency
per 28 days over placebo reached statistical significance for BRV50 (22.0%;
P = 0.004), but not for the other dose
groups (BRV5 or BRV20). In addition,
statistical significance was achieved for
the 50% or greater responder rate in the
BRV50 group compared with placebo
(32.7% versus 16.7%; P = 0.008). BRV50

also displayed benefits with percent
reduction in POS frequency from baseline compared with placebo (30.5% versus
17.8%; P = 0.003). The study concluded
that adjunctive therapy with BRV50 offers
significant reductions in the frequency of
POS when compared with placebo.

Klein et al.8

A randomized, double-blind, placebo-
controlled, multicenter trial conducted
across 147 sites in 27 countries throughout North America, Europe, Latin
America, and Asia evaluated brivaracetam versus placebo in 768 patients
with uncontrolled POS despite treatment
with one or two AEDs. Patients receiving concomitant levetiracetam were
excluded.
Eligible patients were randomized to
receive BRV100, BRV200, or placebo,
administered twice daily in equal doses.
The coprimary efficacy endpoints were
percent reduction over placebo in 28-day
adjusted POS frequency and 50% or greater
responder rate based on percent reduction
in POS frequency from baseline.
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The study met both of its primary efficacy endpoints. Percent reduction in POS
frequency per 28 days over placebo was
22.8% for BRV100 (P < 0.001) and 23.3%
for BRV200 (P < 0.001). Similarly, the 50%
or greater responder rate was 21.6% for
placebo, 38.9% for BRV100 (P < 0.001),
and 37.8% for BRV200 (P < 0.001).
Treatment-related adverse events
occurred in 155 of 261 (59.4%) placebo
patients versus 340 of 503 (67.6%)
brivaracetam patients. (Table 2) Dis
continuation rates due to treatmentrelated adverse effects were 3.8% for
placebo, 8.3% for BRV100, and 6.8%
for BRV200. The study concluded that
adjunctive therapy with BRV100 and
BRV200, without the concomitant use of
levetiracetam, was beneficial in reducing POS frequency in patients with focal
seizures, without resulting in significant
safety or tolerability issues.

Kwan et al.9

A phase 3, double-blind, randomized,
placebo-controlled, flexible-dose trial
conducted across 74 sites in 15 countries throughout Europe and Asia evaluated varying doses of brivaracetam
versus placebo in 480 patients with
uncontrolled epilepsy (431 with POS, 49
with generalized epilepsy).
Eligible patients were randomized to
receive placebo or brivaracetam, administered twice daily in equal doses. The
brivaracetam was initiated at BRV20 and
increased, as needed, to BRV150 during
an eight-week period. This dose-finding
period was followed by an eight-week
fixed-dose maintenance period. The
primary efficacy endpoint was percent
reduction in baseline-adjusted POS
frequency per week.
From October 2007 through December
2008, 90.0% of BRV-treated patients and
91.7% of placebo-treated patients completed the study. Baseline characteristics were largely similar between the two
treatment groups. The study met its primary efficacy endpoint. In patients with
POS, percent reduction in POS frequency
from baseline was 26.9% for brivaracetam
versus 18.9% for placebo (P = 0.070). The
study concluded that adjunctive therapy
with brivaracetam given at individualized
doses ranging from 20–150 mg per day
was well tolerated and effective at reducing seizure frequency in patients with
uncontrolled epilepsy.
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Summary of Meta-Analyses

Three meta-analyses reviewing
the efficacy and safety of brivaracetam as an adjunctive therapy for POS
were identified. The first included six
randomized, placebo-controlled, singleor double-blind add-on trials involving
2,399 patients (1,715 receiving brivaracetam and 684 receiving placebo). The
following endpoints were assessed: 50%
or greater reduction in seizure frequency,
seizure freedom, incidence of treatmentrelated adverse events, and treatment
withdrawal. In regard to all of the primary
endpoints, an x2 test indicated no significant statistical heterogeneity between
the trials. It was determined that 45% of
levetiracetam-naïve patients responded
to brivaracetam and 19% to placebo, suggesting a 25% real response rate that was
not attributable to placebo. Brivaracetam
was found to be more effective than placebo in reducing seizure frequency by
50% or more when added to concomitant
AEDs in patients with refractory partial
epilepsy. While there was insufficient
data to perform a dose–response regression analysis, the results of the trials
suggest that a dose-dependent effect
saturated when the dose of brivaracetam reached 50 mg per day. The authors
concluded that brivaracetam was effective as an add-on treatment in adults with
refractory focal epilepsy and may offer
additional benefits in those patients who
are levetiracetam-naïve.1
The second meta-analysis included
five randomized, double-blind, placebocontrolled, parallel-group trials that
assessed the efficacy and safety of brivaracetam compared with placebo as
adjunctive therapy for patients with
POS. Patients in the trials must have
received at least one concomitant AED
at a stable and optimal dosage prior to
study commencement. Brivaracetam at
doses of 20, 50, 100, and 150 mg per day
was associated with significantly higher
50% responder rates. Brivaracetam 5 mg
per day was not associated with any significant difference in 50% responder rate
when compared with placebo. In addition, treatment-related adverse events
varied depending on the dose. Brivaracetam dosed at 150 mg per day was
more associated with somnolence than
any other dose. Similarly, fatigue and
irritability were associated with brivaracetam 50 mg per day. In conclusion, it

was determined that the use of brivaracetam at doses greater than 5 mg per day
resulted in statistically significant reductions in seizure frequency with respect to
the 50% responder rate. Brivaracetam was
mostly well tolerated, with the exception
of some irritability and somnolence associated with the 50-mg and 150-mg per day
doses, respectively.10
The third meta-analysis included
five randomized, placebo-controlled,
single- or double-blind add-on trials
that investigated the efficacy and
safety of brivaracetam at varying
doses. The following endpoints were
assessed: 50% or greater reduction
in seizure frequency and seizurefree rates. Overall, the 50% responder
rates of patients receiving brivaracetam 20, 50, or 100 mg per day were significantly higher than those receiving
placebo (20 mg: risk ratio [RR] = 1.63,
P = 0.003; 50 mg: RR = 2.00, P < 0.00001;
100 mg: RR = 1.80, P = 0.01). In addition,
patients in all brivaracetam groups experienced higher seizure-free rates when
compared with placebo regardless of
dosage (RR = 4.11, P = 0.01). Patients
receiving brivaracetam of any dosage
experienced significantly higher rates
of adverse effects compared with those
receiving placebo, specifically somnolence (P = 0.02) and fatigue (P = 0.009).
The authors concluded that brivaracetam
demonstrated efficacy as an adjunctive
treatment for refractory POS, as indicated
by its statistically significant increases in
the 50% responder rate (P < 0.00001) and
seizure-free rate (P = 0.01).11

WARNINGS AND PRECAUTIONS

AEDs may increase the risk of
suicidal behaviors or thoughts in patients
taking these medications for any indication. Patients taking brivaracetam should
be monitored for depression, suicidal
ideations, or any unusual changes in
mood and behavior.3
Brivaracetam may also cause dosedependent increases in somnolence and
adverse effects such as fatigue, malaise,
sedation, and lethargy. In the phase 3
controlled, adjunctive epilepsy trials,
these adverse effects were seen in 25%
of patients randomized to receive at least
50 mg per day of brivaracetam compared
with 14% of patients receiving placebo.3
Treatment with brivaracetam is associated with dizziness and disturbances in
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Table 2 Safety Data for Brivaracetam
(100 mg per day)
Adverse Event
(Incidence ≥ 5%)

Rate (%)
Ryvlin et al.6

Klein et al.8

Somnolence

8.0

19.4

Dizziness

5.0

10.3

Fatigue

8.0

7.5

Headache

9.0

6.7

Urinary tract infection

N/R

5.1

Nasopharyngitis

1.0

N/R

Vertigo

2.0

N/R

Nausea

1.0

N/R

Irritability

5.1

N/R

N/R = not reported.

gait and coordination, such as vertigo,
ataxia, and nystagmus. In the phase 3
controlled adjunctive epilepsy trials, these
adverse reactions were reported in 16% of
patients randomized to receive at least
50 mg per day of brivaracetam compared
with 10% of patients receiving placebo.
The risk of gait disturbances is greatest
early in treatment, but may occur at any
time throughout therapy.3
Brivaracetam is also associated with
psychiatric adverse events, including
nonpsychotic symptoms, such as irritability, anxiety, aggression, anger, agitation,
and depression, and psychotic symptoms,
such as paranoia and acute psychosis. In
the phase 3 controlled, adjunctive epilepsy
trials, these adverse reactions were
reported in 13% of patients randomized
to receive at least 50 mg per day of brivaracetam compared with 8% of patients
receiving placebo.3
Brivaracetam is also associated with
hypersensitivity reactions, namely
bronchospasm and angioedema. The
medication should be discontinued in
patients who develop hypersensitivity
reactions after being treated with
brivaracetam.3

DRUG–DRUG INTERACTIONS

Due to the potential for CYP2C19
induction, coadministration with rifampin
decreases the plasma concentrations of
brivaracetam. The dose may need to be
doubled in patients receiving concomitant
treatment with rifampin.3
Coadministration with carbamazepine
may increase exposure to its active metab-

olite, carbamazepine-epoxide.
While existing data did not reveal
any safety concerns in patients
receiving concomitant treatment
with carbamazepine, the dose of
carbamazepine may need to be
reduced if tolerability issues arise
during therapy.3
Because brivaracetam may
increase the plasma concentrations of phenytoin, phenytoin
levels should be monitored
when brivaracetam is added
to or removed from ongoing
phenytoin therapy.3
When coadministered
with levetiracetam, brivaracetam provided no additional
therapeutic benefit.3

SPECIAL POPULATIONS
Pregnancy and Lactation

Brivaracetam is in pregnancy
category C, and there are currently
no well-controlled studies in pregnant
women. However, in animal studies, there
was evidence of developmental toxicity
at plasma exposures greater than clinical exposures. Therefore, brivaracetam
should only be used in pregnant patients
if the potential benefit outweighs the risk
to the fetus. In addition, pregnant patients
taking brivaracetam are advised to enroll
in the North American Antiepileptic Drug
Pregnancy Registry at 1-888-233-2334 or
www.aedpregnancyregistry.org. No data
are available on the excretion of brivaracetam in human milk. However, in rat
studies, it was found that brivaracetam is
excreted in milk.3

Pediatric and Geriatric Use

The safety and efficacy of brivaracetam has not been established in patients
younger than 16 years of age. However, in
juvenile rats and dogs, potential adverse
effects on postnatal growth and development were observed. In addition, in the
double-blinded, placebo-controlled epilepsy trials, there were too few patients
ages 65 years or older to assess the medication’s efficacy. However, dose selection
for elderly patients should begin at the
lower end of the dosing range and should
be made with careful consideration of the
patient’s hepatic function, renal function,
and other drug therapy.3

Renal and Hepatic Impairment

Patients with impaired renal function
do not require dose adjustments of brivaracetam. However, the medication is not
recommended in patients with end-stage
renal disease receiving dialysis because
there are no data in this patient population. For patients with any stage of hepatic
impairment, the recommended starting
dose of brivaracetam is 25 mg twice daily
and the recommended maximum dose is
75 mg twice daily.3

DOSAGE AND ADMINISTRATION

The recommended starting dose for
brivaracetam is 50 mg twice daily (100 mg
total daily dose).3 Gradual dose escalation is not necessary when initiating
treatment. The dosage may be adjusted
down to 50 mg daily or up to 200 mg daily
depending on patient tolerability and
therapeutic response.2 Brivaracetam is
available as an oral tablet (10 mg, 25 mg,
50 mg, 75 mg, and 100 mg), oral solution
(10 mg/mL), and intravenous (IV) injection (50 mg/mL). If oral administration of
brivaracetam is not feasible, the injectable
form may be administered at the same
dosage and frequency as the tablets and
oral solution. However, it is important to
note that the clinical study experience
with brivaracetam injection is limited to
four consecutive days of therapy.3
The oral tablets and solution may be
taken with or without food. Brivaracetam tablets should be swallowed whole
with liquid and not chewed or otherwise
crushed. The oral solution should be measured out and delivered with a calibrated
measuring device in order to accurately
deliver the prescribed dose. The oral solution does not need to be diluted and may
be administered using a nasogastric or
gastrostomy tube. Any unused brivaracetam oral solution should be discarded
after five months of opening the bottle.3
Brivaracetam injection is for IV use
and is single-dose only. The injection
does not need to be diluted, though it
may be mixed with the following diluents:
0.9% sodium chloride injection USP, lactated Ringer’s injection, or 5% dextrose
injection USP. The injection should be
administered over two to 15 minutes. If
diluted, the solution may be stored in
PVC bags, but must not be stored for
more than four hours at room temperature. Generally, the medication may be
stored at 25°C (77°F), with excursions
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permitted between 15°C to 30°C (59°F
to 86°F). The injection and oral solution
formulations should not be frozen.3

COST

Brivaracetam is supplied in three
formulations: 10-mg, 25-mg, 50-mg,
75-mg, and 100-mg tablets; 10-mg/mL
oral solution; and 10-mg/mL injection
for IV administration.3 The 10-mg tablets are available for dose titration. The
average wholesale price (AWP) for a
60-tablet package of all dosages of the
tablet formulation or for the 300-mL bottle
of oral solution is $1,092.12 The AWP for a
package of 10 single-dose 5-mL vials for
IV administration is $468.12

P&T COMMITTEE
CONSIDERATIONS

Brivaracetam is an FDA-approved
medication indicated as adjunctive therapy in patients with POS. Clinical studies
have evaluated the safety and efficacy of
brivaracetam in comparison with treatment with placebo and found that brivaracetam (dosed 50 mg per day, 100 mg
per day, or 200 mg per day) demonstrates
significant reductions in POS frequency
across all doses (P < 0.01 for all arms).
Brivaracetam is available in tablet, oral
solution, and injection formulations with
a price that is comparable to other FDAapproved therapies for adjunctive treatment of POS. The oral formulations are
available with flat pricing; therefore, all
strengths would likely need to be added
to a drug formulary.
Despite promising data from clinical
studies, there is a lack of evidence suggesting that brivaracetam offers any benefit over other AEDs, such as levetiracetam. While the available data suggests
brivaracetam may provide some benefit
over placebo, this is not sufficient cause
for it to be included on hospital formularies. Brivaracetam may have a role as
an adjunctive therapy for patients whose
epilepsy remains uncontrolled despite
taking one to two concomitant AEDs.

CONCLUSION

Brivaracetam is a racetam derivative
and SV2A ligand approved as adjunctive
therapy for the treatment of POS in adults
and adolescents 16 years of age and older.
This medication has shown promise in
patients with epilepsy whose seizures
persist despite adequate treatment.
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Brivaracetam was well tolerated throughout all three phase 3 trials, which led to its
FDA approval. The drug offers improved
seizure control with minimal safety risks
for patients with epilepsy.
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